How much funding has Arbor Biotechnologies raised?

Arbor Biotechnologies has raised $304.5M in total funding, most recently a Series C round.

Who are Arbor Biotechnologies's investors?

Arbor Biotechnologies's investors include ARCH Venture Partners, TCGX, ArrowMark Partners, Deep Track Capital, Section 32.

When was Arbor Biotechnologies founded?

Arbor Biotechnologies was founded in 2016.

Where is Arbor Biotechnologies headquartered?

Arbor Biotechnologies is headquartered in Cambridge, Massachusetts, United States.

What industry is Arbor Biotechnologies in?

Arbor Biotechnologies operates in Biotech, Drug Discovery, Life Sciences, Therapeutics.

How many employees does Arbor Biotechnologies have?

Arbor Biotechnologies has 51-200 employees.

Arbor Biotechnologies

Arbor Biotechnologies™ - Home

Cambridge, United States · Founded 2016 · $304.5M raised

Headquarters: Cambridge, Massachusetts
Employees: 51–200
Founded: 2016
Business Model: B2B

Website: arbor.bio
Total Funding: $304.5M
Last Round: $73.9M Series CMar 2025
Rounds: 3

About

Arbor Biotechnologies is a next-generation gene editing company based in Cambridge, MA, advancing a pipeline of novel genomic medicines for patients with genetic diseases. The company discovers and develops programmable DNA editors — building on CRISPR with advanced proprietary tools — to enable curative outcomes across liver, CNS, and other disease areas. Arbor partners with global pharmaceutical leaders to bring its editing platform to clinical-stage programs.

Summary

Arbor Biotechnologies is a Biotech company based in Cambridge, United States, founded in 2016. It has raised $304.5M in total across 3 rounds, most recently a $73.9M Series C round in Mar 2025. Investors include ARCH Venture Partners, TCGX and ArrowMark Partners.

LinkedIn X (Twitter)